Pfizer Inc. (NYSE:PFE – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors purchased 673,000 call options on the stock. This is an increase of approximately 584% compared to the average daily volume of 98,364 call options.
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
- Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
- Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
- Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips
Pfizer Stock Down 1.7%
PFE stock opened at $29.38 on Friday. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.44. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The business’s 50-day simple moving average is $28.74 and its 200 day simple moving average is $26.90. The company has a market cap of $167.46 billion, a PE ratio of 10.06, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is presently 245.71%.
Institutional Trading of Pfizer
Several large investors have recently added to or reduced their stakes in PFE. Bank of America Corp DE purchased a new stake in Pfizer in the 2nd quarter worth approximately $1,049,602,000. BlackRock Inc. increased its stake in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the period. Nykredit A S acquired a new stake in shares of Pfizer during the second quarter worth $205,774,000. Assenagon Asset Management S.A. boosted its holdings in shares of Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock worth $286,609,000 after purchasing an additional 5,829,204 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after buying an additional 5,501,032 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts have issued reports on the stock. Argus set a $40.00 price target on shares of Pfizer in a research report on Wednesday. JPMorgan Chase & Co. boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. BMO Capital Markets dropped their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Six equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $30.39.
View Our Latest Stock Report on Pfizer
About Pfizer
Read More
- Five stocks we like better than Pfizer
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
